DESIGN, OPTIMISATION AND EVALUATION OF PIROXICAM FAST DISSOLVING TABLETS EMPLOYING STARCH TARTRATE-A NEW SUPERDISINTEGRANT by KUMAR, R. SANTOSH & GHOSH, ANKITA
 
 
DESIGN, OPTIMISATION AND EVALUATION OF PIROXICAM FAST DISSOLVING TABLETS 




GITAM Institute of Pharmacy, GITAM Deemed to be University, Rushikonda, Visakhapatnam, A. P 530045, India 
Email: drsantoshrada@gmail.com 
, ANKITA GHOSH 
Received: 24 Sep 2018, Revised and Accepted: 05 Mar 2019 
ABSTRACT 
Objective: To enhance the solubility of poorly soluble drugs by evaluating starch tartrate as a superdisintegrant in the formulation of fast dissolving 
tablets by employing 23
Methods: Starch tartrate was synthesized by gelatinization process. The physical and micromeritic properties were performed to evaluate the 
synthesized starch tartrate. The fast dissolving tablets of piroxicam were prepared by using starch tartrate as a superdisintegrant in different 
proportions by direct compression technique using 2
 factorial design. 
3 factorial design. The drug content, hardness, friability, disintegration time and other 
dissolution characteristics like percent dissolved in 5 min (PD5), dissolution efficiency in 5 min (DE5%) and first-order rate constant (K1
Results: The superdisintegrant starch tartrate prepared was found to be fine, free-flowing slightly crystalline powder. Starch tartrate exhibited 
good swelling in water. The study between piroxicam and starch tartrate was shown the absence of interaction by fourier transform infrared 
spectra (FTIR) and differential scanning calorimetry (DSC). The drug content (99.83±0.56 %), hardness (3.7–3.9 kg/sq. Cm), and friability (0.12-
0.15%) have been effective with regard to all the formulated fast dissolving tablets employing starch tartrate. The disintegration time of all the 
formulated fast dissolving tablets (FDTs) was found to be in the range of 12±0. 01 to 4500±0.02s. The optimized formulation F6 has the least 
disintegration time i.e., 12±0. 01s. The In vitro wetting time of the formulated tablets was found to be in the range of 35±0.09 to 1624±0.02s. The In–
Vitro wetting time was less (i.e., 90s) in optimized formulation F6. The water absorption ratio of the formulated tablets was found to be in the range 
of 60±0.12 to 65±0.15%. The cumulative drug dissolved in the optimized formulation F6 was found to be 99.32±0.09% in 10 min.  
) were used 
in the evaluation of prepared fast dissolving tablets. 
Conclusion: The dissolution efficiency of piroxicam was enhanced when starch tartrate was found to be a superdisintegrant when combined with 
crospovidone and, hence it could be used in the formulation of fast dissolving tablets to provide immediate release of the contained drug within 10 min. 
Keywords: Fast dissolving, Superdisintegrant, Starch tartrate, Dissolution efficiency 




Drug delivery systems are tools for expanding markets, 
extending product life cycles and generating opportunities. Oral 
administration is the most common route for systemic action 
due to easy ingestion, pain, avoidance, versatility and patient 
compliance. Parentrals are generally not preferred by patients. 
The preference for solid dosage forms that can be dissolved and 
suspended in water, chewed, or rapidly dissolved in the mouth is 
particularly more in the pediatric and geriatric patients, with 
further application to other patients who prefer an easily 
administered dosage form.  
Because of the increase in the average human lifespan and the 
decline of swallowing ability with age, oral administration of 
dosage forms to patients is a significant problem and has become 
the object of public attention. The problem can be resolved by 
developing rapidly dispersing or dissolving oral forms, which 
does not require water for swallowing. The dosage forms are 
allowed to disperse or dissolve in the saliva when placed in the 
mouth and then are swallowed normally. The bioavailability of a 
drug from fast dissolving formulations may be even greater than 
standard dosage forms. In some cases, problems related to 
motion sickness, sudden allergic attacks and unavailability of 
water to swallow conventional tablets can be resolved by use of 
fast disintegrating tablets. When placed on the tongue, this tablet 
disintegrates immediately, releases the drug, which dissolves in 
the saliva.  
The present investigation involved in the preparation and evaluation 
of starch tartrate as superdisintegrant in the formulation of fast 
dissolving tablets of poorly soluble drugs like piroxicam. Therefore 
the solubility and dissolution rate of piroxicam can be enhanced 
resulting in greater bioavailability of drugs [1-5]. 
MATERIALS AND METHODS 
Materials 
Sodium hydroxide, tartaric acid, carbon disulfide, mannitol was 
purchased from Finar chemicals Ltd, Ahmedabad. Potato starch, 
piroxicam, crospovidone, croscarmellose sodium was obtained from 
Yarrow chem. products, Mumbai. Microcrystalline cellulose was 
bought from Qualigens fine chemicals, Mumbai. Talc and magnesium 
stearate was obtained from Molychem, Mumbai. 
Preparation of starch tartrate (a novel superdisintegrant) 
Initially, 10 parts of tartaric acid were dissolved in 25 ml of distilled 
water. The pH of the dispersion was checked. If pH was not 3.5, the 
10 (M) sodium hydroxide solution was added to adjust to pH 3.5. 
This dispersion was conditioned for 16 h. After 16 h it was dried in 
the oven at 60 °C until it gets dried. The mass was washed with 
distilled water to remove the unreacted tartaric acid. The product 
was kept in the oven at 60 °C until it gets dried. The product 
obtained was ground and sieved (# 80).  
Characterization of starch tartrate 
The starch tartrate prepared was evaluated for the following 
Solubility 
The solubility of starch tartrate was tested in distilled water, an 
aqueous buffer of pH 1, 2, 3, 4, 5, 6, and 7.4 and organic solvents such 
as alcohol, dichloromethane, chloroform, acetone and petroleum 
ether [6]. 
pH 
The pH of 6% w/v slurry was measured by pH meter [6]. 
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Melting point was determined by using melting point apparatus [6]. 
Viscosity 
The viscosity of 1% dispersion in water was measured using 
Ostwald Viscometer [6]. 
Swelling index 
Starch tartrate (200 mg) was added to 10 ml of water and light 
liquid paraffin was taken in two different measuring cylinders and 
mixed. The dispersion in the tubes was allowed to stand for 12 h. 
The volumes of the sediment in the cylinders were recorded. The 
swelling index of the material was calculated as follows [7]. 
 
Test for gelling property  
The gelling property (gelatinization) of the starch and prepared 
starch tartrate, was evaluated by heating a 7% w/v dispersion of 
each in water at 100 °C for 30 min [7]. 
Particle size 
Particle size analysis was done by sieving using standard sieves [7]. 
Density 
Density (g/cc) was determined by liquid displacement method using 
benzene as liquid [7]. 
Bulk density 
Both loose bulk density (LBD) and tapped bulk density (TBD) were 
determined by transferring the accurately weighed amount of 
sample in 50 ml measuring cylinder, and tapped 50 times on a plane 
surface and tapped volume of packing recorded and LBD and TBD 
calculated by the following formula [8]. 
 
 
Percentage compressibility index  
Percentage compressibility of the powder mix was determined by 
Carr's Compressibility Index calculated by the following formula [9]. 
 
Where TBD= Tapped bulk density; LBD= Loose bulk density. 
Angle of repose 
The frictional forces in loose powder or granules can be measured 
by the angle of repose. This is the maximum angle possible between 
the surface of a mass of powder and the horizontal plane. The angle 
of repose is calculated by applying the next equation [9]; 
  
Where θ=angle of repose; h=height of the pile of powder; r=radius of 
the pile of powder 
Fourier transform infrared (FTIR) spectroscopy 
FTIR spectra of starch tartrate were recorded on samples prepared 
in potassium bromide (KBr) disks using a BRUKER FT–IR,(Tokyo, 
Japan). The scanning range was 500 to 4000 cm-1
X-Ray diffraction 
. Samples were 
mixed with (KBr) to form disks by means of a hydrostatic press at 6-
8 tons pressure [8]. 
The diffraction pattern of starch tartrate was recorded with an x-ray 
diffractometer (analytical spectra’s Pvt. Ltd., Singapore). X-ray 
diffraction was performed at room temperature (30 °C) with a 
diffractometer; target, Cu(λ1.54 A), filter, Ni; voltage,40 ⱪV; current 
30mA; time constant 10 mm/s; scanning rate 2 °/min; measured 
from 10-35 ° at full scale 200 [8]. 
Drug–excipients compatibility studies 
The compatibility of starch tartrate with the selected drug 
(piroxicam) was evaluated in DSC and FTIR studies. 
Differential scanning calorimetry (DSC) 
DSC thermograms of piroxicam and their mixtures (1: 1) with starch 
tartrate were recorded on Perkin Elmer thermal analyzer samples 
(2-5 mg) were sealed into aluminum pans and scanned at a heating 
rate of 10 °C min-1
The tablets were prepared by direct compression technique using 2
 over a temperature range 30–350 °C [8]. 
Infrared spectroscopy 
Fourier transform infrared (FTIR) spectra of piroxicam and their 
mixtures (1: 1) with starch tartrate were recorded on a Perkin 
Elmer, IR Spectrophotometer model: Spectrum RXI, using KBr disc 
as reference [8, 9]. 




factorial design in which 3 independent variables {superdisintegrants 
i.e., starch tartrate (A), crospovidone (B), croscarmellose sodium (C)} 
and 1 dependent variable (dissolution efficiency in 5 min) were taken 
into consideration. The composition of the different formulation of 
piroxicam fast dissolving tablets is shown in table no 1 in which the 
levels of superdisintegrants were selected at 2 levels i.e., lower and 
higher level concentrations. For starch tartrate (A), the lower level i.e. 
0% concentration and upper level i.e. 5% concentration. For 
crospovidone (B) and croscarmellose sodium(C) also, the lower level 
is 0% concentration and higher level i.e., 5% concentration. For 
uniformity in particle size, each ingredient was passed through # 100 
mesh sized screen before mixing. Starch tartrate, crospovidone, 
croscarmellose sodium, mannitol, and microcrystalline cellulose were 
accurately weighed, transferred and mixed using a mortar and pestle, 
and then added to piroxicam. Finally, talc and magnesium stearate 
were added to the powder mixture. Finally, the mixed blend was 
compressed by using eight station rotator press Karnawathi 
Machineries Pvt, Ltd., Ahmedabad, India). 
Table 1: Formulae of piroxicam fast dissolving tablets employing starch tartrate 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 
Piroxicam 20 20 20 20 20 20 20 20 
Starch Tartrate - 10 - 10 - 10 - 10 
Crosscarmellose - - 10 10 - - 10 10 
Crospovidone - - - - 10 10 10 10 
Mannitol72  62 62 52 62 52 52 42 
Micro crystalline cellulose 100 100 100 100 100 100 100 100 
Talc 4 4 4 4 4 4 4 4 
Magnesium state 4 4 4 4 4 4 4 4 
Total 200 200 200 200 200 200 200 200 
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Evaluation of piroxicam fast dissolving tablets 
Hardness test 
Hardness indicates the ability of a tablet to withstand mechanical 
shocks while handling. By using Monsanto hardness tester, the 
hardness of tablets was determined and expressed in kg/cm² [9]  
Uniformity of weight 
Weight variation test was done with 20 tablets. It is the individual 
variation of the tablet weighed from the average weight of 20 tablets 
[10]. 
Friability 
The friability of tablets was measured using a Roche fribilator. 
Tablets were rotated at 25 rpm for 4 min or up to 100 revolutions. 
The tablets were reweighed after removing all the fines and the 
percentage of weight loss was calculated [10]. 
F  
Drug content uniformity 
For content uniformity, ten tablets were weighed and powdered. A 
quantity of powder equivalent to 10 mg of piroxicam was extracted into 
7.2 phosphate buffer and filtered. The piroxicam content was 
determined by measuring the absorbance spectrophotometrically at 221 
nm after appropriate dilution with 7.2 phosphate buffer. The drug 
content was calculated as an average of three determinations [11]. 
Wetting time 
The wetting time of tablets was measured by placing five circular tissue 
papers in a petri dish of 10 cm in diameter. 10 ml of water containing a 
water-soluble dye (amaranth) was added to the petri dish. A tablet was 
carefully placed on the tissue paper. The time required for water to reach 
the upper surface of the tablet was noted as wetting time [12, 13].  
Water absorption ratio 
A piece of tissue paper folded was kept in a small petri dish to which 6 ml 
of water was added. A tablet was kept on the tissue paper and allowed to 
completely wet. The wetted tablet was then weighed. Water absorption 





 = weight of tablet after water absorption. 
2
In–vitro disintegration time 
 = weight of tablet before water absorption. 
Disintegration time for FDTs was determined using USP 
disintegration apparatus 0.1 N HCl buffer. The volume of medium 
was 900 ml and the temperature was 37±0.2 °C. The time taken for 
complete disintegration of the tablet was measured [14]. 
In–vitro dissolution studies  
The in vitro dissolution rate study of piroxicam fast dissolving 
tablets were performed using 8 stage dissolution test apparatus 
(Electrolab TDT-08L) fitted with paddles (50 rpm) at 37±0.5 °C, 
using 7.2 phosphate buffer (900 ml) as a dissolution media. At the 
predetermined time intervals, 5 ml samples were withdrawn, 
filtered through 0.45µ membrane filter, diluted and assayed at 221 
nm using an Analytical technology T360 UV/Visible Double beam 
spectrophotometer. Cumulative percentage release was calculated 
using standard absorbance from the calibration curve. All the 
dissolution experiments were conducted in triplicate (n = 3). 
RESULTS AND DISCUSSION 
The starch tartrate prepared was found to be fine, free-flowing 
slightly crystalline powder. The physical and micromeritics 
properties of the starch tartrate are summarized in table 2. It was 
insoluble in aqueous solvents and insoluble in organic solvents 
tested (methanol, petroleum ether, dichloromethane, and 
chloroform) the pH of 0.1% aqueous dispersion was 3.85. 
Starch tartrate exhibited good swelling in water. The swelling index 
was found to be 100% indicating that it is suitable for 
superdisintegrant. All micrometric properties indicated good flow 
properties needed manufacturing of tablets. The density of starch 
tartrate was found to be 0.625 g/cc. The angle of repose and 
compressibility index showed good flow properties of starch 
tartrate. The FTIR spectrum of potato starch and starch tartrate is 
shown in fig. 1 and 2. The presence of peaks absorption at 1736.63 
cm-1 characteristic peaks of ester, so from FTIR studies it was 
concluded that starch tartrate (ester) was formed when starch was 
allowed to react with tartaric acid. The X-ray diffraction pattern (fig. 
3) of starch tartrate showed characteristic peaks, which indicates 
that the structure is slightly crystalline. The disappearance of pink 
color in the ester test confirmed the presence of ester, i.e., starch 
tartrate. As the starch tartrate was slightly crystalline powder and it 
had got all the characteristic of superdisintegrants it was concluded 
that starch tartrate can be used as novel superdisintegrant in the 
formulation of fast dissolving tablets. 
 
Table 2: Physical and micromeritics properties of the starch tartrate prepared 
Parameters Observation 
Solubility Insoluble in all aqueous and organic solvents tested 
pH(1% w/v aqueous dispersion) 3.85±0.01 
Melting Point( °C) 270±0.02  
Viscosity(1% w/v aqueous dispersion in cps) 1.1034±0.001 
Swelling index(%) 66.5±0.05 
Gelling property No gelling at 100 ˚C but formed a clear solution. Whereas in the case of starch, it was gelatinized 
and formed a gel. 
Particle Size(µm) 142±0.02 
Density(g/cc) 0.625±0.001 
Bulk Density(g/cc) 0.714±0.003 
Angle of Repose( °) 23.6±0.02 
Compressibility Index(%) 13±0.05 
*SD Standard Deviation from mean, n=3 
 
The compatibility of starch tartrate with the selected drug (piroxicam) 
was evaluated by DSC, FTIR studies. The DSC thermograms of 
piroxicam and piroxicam–starch tartrate are shown in fig. 5.2 and 5.3. 
The DSC thermograms of piroxicam and piroxicam–starch tartrate 
exhibited exothermic peaks at 203.17 ̊C and 198.99˚C respectively. 
These melting peaks of piroxicam and piroxicam–starch tartrate 
correspond to the melting points of piroxicam (198-200 ˚C). The peaks 
observed in the DSC thermograms of piroxicam and piroxicam–starch 
tartrate mixtures correspond to the melting points of the respective 
drug indicating no interactions between the selected drug and starch 
tartrate polymer. The DSC study, thus, indicated no interaction 
between starch tartrate and selected drug. 
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Fig. 1: Fourier transform infrared spectra of potato starch 
 
 
Fig. 2: Fourier transform infrared spectra of starch tartrate 
 
 
Fig. 3: X-Ray diffraction pattern of starch tartrate 
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Fig. 4: DSC thermogram of piroxicam pure drug 
 
 
Fig. 5: DSC thermogram of piroxicam with starch tartrate 
 




























































































































Fig. 6: FTIR spectra of piroxicam 
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Fig. 7: FTIR spectra of piroxicam with starch tartrate 
 
The FTIR spectra of piroxicam and piroxicam–starch tartrate are shown 
in Figs.5.4 and5.5. The characteristic FTIR bands of piroxicam at 3338.18 
cm-1 (NH), 1632.87 cm-1 (C=O), 1434.56 cm-1 (CN) and piroxicam-
starch tartrate at 3337.33 cm-1 (NH), 1633.31 cm-1 (C=O), 1433.14 cm-
1 (CN) were all observed in the FTIR spectra of both piroxicam and 
piroxicam–starch tartrate. These FTIR spectra observations also 
indicated no interaction between starch tartrate and the drug selected. 
Thus the results of DSC and FTIR indicated no interaction between 
the selected drug and starch tartrate, the new superdisintegrant. 
Hence starch tartrate could be used as a superdisintegrant in the 
design of fast dissolving tablets of the selected drug. 
Evaluation of tablets 
Hardness 
The hardness of tablets from all batches was found to be in the range 
of 3.6–4 kg/sq. cm. All tablets were found hard enough so that they 
could easily withstand the handling and storage conditions without 
getting broken. 
Friability 
The percent friability of all batches found less than 0.15 % indicating 
the good mechanical resistance of tablets. Thus, it was proved that 
tablets could withstand the pressure, mechanical shocks during 
handling, transportation, storage, and manufacturing processes. 
Drug content 
Drug content of all the formulation batches was found to be 
100±5%. Hence, it can be concluded that all the formulations are 
having an accurate amount of drug distributed uniformly in powder 
mass and followed acceptable limits as per IP [15]. i.e. 85 to 115 % 
of average content table 3. 
Disintegration studies 
In vitro disintegration time was done by the USP dissolution 
apparatus. The disintegration rate has a correlation with water 
absorption. The In vitro disintegration time was found between 
12±0.02 to 4500±0.02 seconds. The outcomes were tabulated and 
data demonstrated in table 3. All the formulation showed 
disintegration time of less than 180 s. It was found that the 
formulation F6 will show least disintegration time 12s as compared 
to other formulation. The order for a disintegration time in fast 
dissolving tablet was found to be F6<F5<F7<F8<F3<F4<F2<F1. The 
order of disintegration time may be due to the interaction and main 
effects of the super disintegrants used in the fast dissolving tablets. 
Water absorption ratio and wetting time 
The water absorption ratio founded between 38.5±0.12%-65.2±0.15%. 
The increase in behavior due to the water uptake ability of super 
disintegrants, the wetting time was found between 35±0.0-1624.2±0.02 
seconds. The outcomes were tabulated and data demonstrated in table 3 
and fig. 8 and 8a. It was found that the formulation F6 containing 10 % 
starch tartrate and 10 % crospovidone showed less wetting time i.e. as 
35±0.09 seconds compared to other formulations. 
In vitro dissolution studies 
Dissolution rate depends on the wetting time of the disintegrant, 
among all the formulations F6 has less wetting time and has greater 
dissolution rate and then this is the other conformance test for 
correct selection of desirable. In vitro dissolution studies of all the 
formulation were done and depicted in fig. 9. In all formulations, F6 
formulation was selected as the promising formulation containing 5 
% starch tartrate and 5 % crospovidone with 99.32%±0.05 release 
in 5 min which may be due to the interaction effect between the two 
super disintegrants i.e., starch tartrate and crospovidone at a 
concentration of 5 % each.  
The dissolution parameters of the formulation from (F1–F8) which 
were made by direct compression method were shown in the table 
4. In all these cases the PD5 (percent dissolved in 5 min) was more in 
F6 which consists at 5% starch tartrate, and 5% crospovidone. The 
same was in the case of DE5% (dissolution efficiency in 5 min). The 
PD5 and DE5% revels that starch tartrate was effective at 5% along 
with 5% crospovidone when the formulations were made by direct 
compression using these superdisintegrants. The K1 decreased in all 
the formulation when compared to F1 formulation which was given 
in table 4. The number of folds increases in DE5% and the number of 
folds increase in K1 (min-1) were given to the table 4. From the 
results, it was concluded that starch tartrate (new 
superdisintegrant) could be used as a superdisintegrant in the 
formulation of fast dissolving tablets of piroxicam. To evaluate the 
individual and combined effects of the three factors involved, fast 
dissolving tablets were formulated employing selected combinations 
of the factors as per 23-factorial design. The fast dissolving tablets 
and release parameters (percent drug released in 5 min) of the fast 
dissolving formulated were analyzed as per ANOVA of 23-factorial 
design. ANOVA of disintegrating times and dissolution efficiency in 5 
min (table 5 and 6) indicated that the individual effects of starch 
tartrate (A), sodium starch glycolate (B) and crospovidone (C), as 
well as the combined effects of AB, AC, BC and ABC factors, were 
significant (P<0.05) on disintegration time and dissolution efficiency 
in 5 min of piroxicam fast dissolving tablets.  
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Fast dissolving tablets formulated employing starch tartrate 
(5%), sodium starch glycolate (5%) and crospovidone (5%) as 
superdisintegrants exhibited good disintegration and dissolution 
efficiency in 5 min. Formulation F6 gave release of 99.32%±0.05 
in 10 min fulfilling the official specification, based on 
disintegration time and dissolution efficiency in 10 min. 
Formulation F6 is considered as a good fast dissolving tablet 
formulation of piroxicam which was found to better than the 
piroxicam fast dissolving tablets formulated by Sachan Anupam 
et al. [15]. 
 





) Friability (%) 
n±SD 
Drug Content (mg/tab) 
n±SD 
Disintegration Time (sec) 
n±SD 
Water Absorption Ratio (%) 
n±SD 
F1 3.7±0.01 0.12±0.013 97.58±0.71 4500±0.02 38.5±0.12 
F2 3.7±0.03 0.13±0.015 98.1±0.79 309±0.03 52.6±0.18 
F3 3.7±0.01 0.14±0.012 99.45±0.63 72±0. 02 62.8±0.16 
F4 3.7±0.04 0.12±0.014 98.56±0.55 144±0. 02 57.9±0.15 
F5 3.8±0.03 0.14±0.012 99.83±0.56 12±0.01 57.4±0.21 
F6 3.9±0.01 0.15±0.012 99.34±0.18 15±0.02 60.1±0.12 
F7 3.8±0.02 0.14±0.014 99.56±0.57 23±0. 01 65.2±0.15 
F8 3.7±0.04 0.12±0.013 99.17±0.11 26±0.02 64.1±0.27 
*SD Standard Deviation from the mean, n=3 
 
 
Fig. 8: Piroxicam fast dissolving tablets prepared employing starch tartrate involving mannitol as a diluents 
 
 
Fig. 9: Dissolution profiles of piroxicam fast dissolving tablets (F1-F4) (n=3, mean±SD) 
Santosh et al. 




Fig. 10: Dissolution profiles of piroxicam fast dissolving tablets (F5-F8) (n=3, mean±SD) 
 
 
Fig. 10: Time Vs
 
 Log percent drug undissolved plots for piroxicam fast dissolving tablets (F1-F8) (n=3, mean±SD) 
Table 4: Piroxicam percent dissolved from fast dissolving tablets employing starch tartrate 
Time (min) F1 F2 F3 F4 F5 F6 F7 F8 
PD 1.61±0.74 5 2.44±0.74 41.23±0.67 30.82±0.82 58.83±0.21 61.66±0.75 46.89±0.99 41.24±0.36 
DE5 1.1±0.01 % 1.3±0.02 22.8±0.05 16±0.02 31.6±0.01 34.8±0.05 27.4±0.02 23.4±0.03 





1.18 20.72 14.54 28.72 31.63 24.90 21.27 
K1 (min-1 0.001±0.001 ) 0.0154±0.003 0.1123±0.005 0.0536±0.002 0.2378±0.001 0.1842±0.002 0.1278±0.002 0.0921±0.005 





15.4 112.3 53.6 237.8 184.2 127.8 92.1 
*SD Standard Deviation from mean, n=3, PD5-Percent dissolved in 5 min., DE5%-Dissolution efficiency in 5 min., K1 =First Order Rate Constant 
 
Table 5: ANOVA of disintegration time of piroxicam fast dissolving tablets formulated employing starch tartrate 
Source of variation d. f S. S M. S. S ratio Variance Result 
Replicates 2 1764.58 882.29 0.93 P>0.05 
Treatments 7 53155337.96 7593619.70 8061.59 P ˂ 0.05 
Starch Tartrate (A) 1 6595065.04 6595065.04 7001.50 P ˂ 0.05 
Croscarmellose sodium (B) 1 8107275.04 8107275.04 8606.90 P ˂ 0.05 
Starch Tartrate× 
Croscarmellose sodium (AB) 
1 7044917.04 7044917.04 7479.07 P ˂ 0.05 
Crospovidone (C) 1 9453915.37 9453915.37 10036.53 P ˂ 0.05 
Starch Tartrate× 
Crospovidone(AC) 
1 6628657.04 6628657.04 7037.16 P ˂ 0.05 
Crospovidone× 
Croscarmellose sodium (BC) 
1 82837.50 82837.50 87.94 P ˂ 0.05 
Starch Tartrate× 
Croscarmellose 
sodium × Crospovidone (ABC) 
1 7040583.37 7040583.37 7474.47 P ˂ 0.05 
Error 14 13187.42 941.95 -- -- 
Total 23 -- -- -- -- 
*SD Standard Deviation from mean, n=3, P<0.05 indicate significance; p>0.05 indicate non-significance, d. f–Degree of Freedom *S. S–Sum of Square 
*M. S. S–Mean Sum of Squares, ANOVA= Analysis of Variance. 
Santosh et al. 
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Table 5: ANOVA of piroxicam fast dissolving tablets formulated employing starch tartrate 
Source of variation d. f S. S M. S. S Variance Result 
 ratio 
Replicates 2 319.78 159.89 2.40 P>0.05 
Treatments 7 17805.68 2543.66 38.23 P ˂ 0.05 
Starch Tartrate (A) 1 345.19 345.19 5.18 P ˂ 0.05 
Croscarmellose sodium (B) 1 326.42 326.42 4.90 P ˂ 0.05 
Starch Tartrate× 1 1376.53 1376.53 20.69 P ˂ 0.05 
Croscarmellose sodium (AB)      
Crospovidone (C) 1 7022.97 7022.97 105.56 P ˂ 0.05 
Starch Tartrate× 1 42.72 42.72 0.64 P>0.05 
Crospovidone(AC)      
Crospovidone× 1 4177.80 4177.80 62.79 P ˂ 0.05 
Croscarmellose sodium (BC)      
Starch Tartrate× 1 139.58 139.58 2.09 P>0.05 
Croscarmellose      
sodium×      
Crospovidone (ABC)      
Error 14 931.42 66.53 -- -- 
Total 23 -- -- -- -- 
P<0.05 indicate significance; p>0.05 indicate non-significance d. f–Degree of Freedom * S. S–Sum of Square * M. S. S–Mean Sum of Squares 
 
CONCLUSION 
Starch tartrate is an efficient superdisintegrant for fast dissolving 
tablets. The disintegration and dissolution efficiency in 5 min of the 
fast dissolving tablets of piroxicam was good and depended on the 
concentration of superdisintegrant employed i.e., starch tartrate and 
crospovidone. 
The piroxicam drug release from the F6 fast dissolving tablets, 
employing starch tartrate (5%) and crospovidone (5%) by direct 
compression was 99.32%±0.05 within 10 min. Overall, starch 
tartrate was found to be a superdisintegrant which enhanced the 
dissolution efficiency of piroxicam when combined with 
crospovidone, and hence it could be used in the formulation of fast 
dissolving tablets to provide immediate release of the contained 
drug within 10 min. 
ABBREVIATION 
FDTs–fast dissolving tablets, FTIR-fourier transform infrared 
spectra, DSC-differential scanning calorimetry, ANOVA–analysis of 
variance 
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